Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
CALGARY, Alberta, July 8, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink"). The closing of the ...
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
CALGARY, Alberta, June 22, 2015 /PRNewswire/ -- Resverlogix Corp. (TSX: RVX) today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update w...
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
CALGARY, Alberta, June 1, 2015 /PRNewswire/ -- Resverlogix Corp. (TSX: RVX) (the "Company") today announced that new data on RVX-208 was presented at the ERA-EDTA Congress inLondon, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal ...
Resverlogix Receives Two Patents for RVX-208 in China
CALGARY, Alberta, April 7, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment o...
